Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H 1 blocker terfenadine-induced torsades de pointes arrhythmias

British Journal of Pharmacology

Volumn 147, Issue 6, 2006, Pages 634-641

  Takahara, Akira ^a   Sugiyama, Atsushi ^a   Ishida, Yuko ^a   Satoh, Yoshioki ^a   Wang, Kai ^a   Nakamura, Yuji ^a   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chronic atrioventricular block dog; QT interval prolongation; Terfenadine; Torsades de pointes

Indexed keywords

HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM; HEART REPOLARIZATION; HEART VENTRICLE; HEART VENTRICLE REMODELING; IN VIVO STUDY; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; TORSADE DES POINTES;

ANIMALS; ATRIOVENTRICULAR NODE; BRADYCARDIA; CATHETER ABLATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART; HEART BLOCK; HISTAMINE H1 ANTAGONISTS; LONG QT SYNDROME; MODELS, ANIMAL; TERFENADINE; TIME FACTORS; TORSADES DE POINTES;

EID: 33645098984     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706493     Document Type: Article

References (45)

1. BATEY, A.J. & COKER, S.J. (2002). Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br. J. Pharmacol., 135, 1003-1012.
2. BELARDINELLI, L., ANTZELEVITCH, C. & VOS, M.A. (2003). Assessing predictors of drug-induced torsade de pointes. Trends. Pharmacol. Sci., 24, 619-625.
3. BILICZKI, P., VIRÁG, L., IOST, N., PAPP, J.G. & VARRÓ, A. (2002). Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br. J. Pharmacol., 137, 361-368.
4. BRENNAN, M., PALANISWAMI, M. & KAMEN, P. (2001). Do existing measures of Poincaré plot geometry reflect nonlinear features of heart rate variability? IEEE Trans. Biomed. Eng., 48, 1342-1347.
5. CARLSSON, L., ALMGREN, O. & DUKER, G. (1990). QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol., 16, 276-285.
6. CARLSSON, L., AMOS, G.J., ANDERSSON, B., DREWS, L., DUKER, G. & WADSTEDT, G. (1997). Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J. Pharmacol. Exp. Ther., 282, 220-227.
7. CHIBA, K., SUGIYAMA, A., HAGIWARA, T., TAKAHASHI, S., TAKASUNA, K. & HASHIMOTO, K. (2004). In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur. J. Pharmacol., 486, 189-200.
8. ECKARDT, L., BREITHARDT, G. & HAVERKAMP, W. (2002). Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J. Pharmacol. Exp. Ther., 300, 64-71.
9. FERGUSON, J., MACDONALD, K.J. & KENICER, K.J. (1985). Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study. Br. J. Clin. Pharmacol., 20, 639-641.
10. GEELEN, P., DROLET, B., RAIL, J., BERUBE, J., DALEAU, P., ROUSSEAU, G., CARDINAL, R., O'HARA, G.E. & TURGEON, J. (2000). Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation, 102, 275-277.
11. GINTANT, G.A., LIMBERIS, J.T., McDERMOTT, J.S., WEGNER, C.D. & COX, B.F. (2001). The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol., 37, 607-618.
12. HONDEGHEM, L.M. & HOFFMANN, P. (2003). Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J. Cardiovasc. Pharmacol., 41, 14-24.
13. LALONDE, R.L., LESSARD, D. & GAUDREAULT, J. (1996). Population pharmacokinetics of terfenadine. Pharm. Res., 13, 832-838.
14. 2+ channel current in rat ventricular myocytes by terfenadine. Circ. Res., 81, 202-210.
15. 1-adrenoceptor stimulation. J. Cardiovasc. Pharmacol., 36, 728-736.
16. MASUMIYA, H., SAITO, M., ITO, M., MATSUDA, T., NOGUCHI, K., IIDA-TANAKA, N., TANAKA, H. & SHIGENOBU, K. (2004). Lack of action potential-prolonging effect of terfenadine on rabbit myocardial tissue preparations. Biol. Pharm. Bull., 27, 131-135.
17. + channels in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol., 26, 761-769.
18. MONAHAN, B.P., FERGUSON, C.L., KILLEAVY, E.S., LLOYD, B.K., TROY, J. & CANTILENA JR, L.R. (1990). Torsades de pointes occurring in association with terfenadine use. JAMA, 264, 2788-2790.
19. PINNEY, S.P., KOLLER, B.S., FRANZ, M.R. & WOOSLEY, R.L. (1995). Terfenadine increases the QT interval in isolated guinea pig heart. J. Cardiovasc. Pharmacol., 25, 30-34.
20. REDFERN, W.S., CARLSSON, L., DAVIS, A.S., LYNCH, W.G., MACKENZIE, I., PALETHORPE, S., SIEGL, P.K., STRANG, I., SULLIVAN, A.T., WALLIS, R., CAMM, A.J. & HAMMOND, T.G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
21. RODEN, D.M. (1998). Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing. Clin. Electrophysiol., 21, 1029-1034.
22. SATOH, T. & ZIPES, D.P. (1996). Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs. Circulation, 94, 217-227.
23. SATOH, Y., SUGIYAMA, A., TAKAHARA, A., ANDO, K., WANG, K., HONSHO, S. & HASHIMOTO, K. (2005). The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. J. Pharmacol. Sci., 97, 101-106.
24. SATOH, Y., SUGIYAMA, A., TAKAHARA, A., CHIBA, K. & HASHIMOTO, K. (2004). Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J. Cardiovasc. Pharmacol., 43, 715-723.
25. SCHNEIDER, J., HAUSER, R., ANDREAS, J.O., LINZ, K. & JAHNEL, U. (2005). Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur. J. Pharmacol., 512, 53-60.
26. SCHOENMAKERS, M., RAMAKERS, C., VAN OPSTAL, J.M., LEUNISSEN, J.D., LONDONO, C. & VOS, M.A. (2003). Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc. Res., 59, 351-359.
27. SHIINA, H., SUGIYAMA, A., TAKAHARA, A., SATOH, Y. & HASHIMOTO, K. (2000). Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring. Jpn. Circ. J., 64, 777-782.
28. Ks downregulation in canine ventricular hypertrophy confers the loss of β-adrenergic-induced shortening of repolarization, favoring proarrhythmia. Circulation, 110 (Suppl III), III-319.
29. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn. J. Pharmacol., 88, 414-421.
30. SUGIYAMA, A., ISHIDA, Y., SATOH, Y., AOKI, S., HORI, M., AKIE, Y., KOBAYASHI, Y. & HASHIMOTO, K. (2002a). Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn. J. Pharmacol., 88, 341-350.
31. SUGIYAMA, A., MOTOMURA, S. & HASHIMOTO, K. (1994). Utilization of an isolated, blood-perfused canine papillary muscle preparation as a model to assess efficacy and adversity of class I antiarrhythmic drugs. Jpn. J. Pharmacol., 66, 303-316.
32. SUGIYAMA, A., SATOH, Y., SHIINA, H., TAKAHARA, A., YONEYAMA, M. & HASHIMOTO, K. (2001). Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J. Cardiovasc. Pharmacol., 38, 940-946.
33. SUGIYAMA, A., SATOH, Y., SHIINA, H., TAKEDA, S. & HASHIMOTO, K. (2002b). Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J. Cardiovasc. Pharmacol., 40, 235-245.
34. TAKAHARA, A., SUGIYAMA, A. & HASHIMOTO, K. (2005). Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation. Br. J. Pharmacol., 146, 561-567.
35. 2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs. J. Pharmacol. Sci., 96, 219-223.
36. TARANTINO, P., APPLETON, N. & LANSDELL, K. (2005). Effect of trazodone on hERG channel current and QT-interval. Eur. J. Pharmacol., 510, 75-85.
37. THE ICH STEERING COMMITTEE. (2005). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH). The Guideline was recommended for adoption at Step 4 of the ICH process in May 2005 (http://www.ich.org/).
38. THOMSEN, M.B., VERDUYN, S.C., STENGL, M., BEEKMAN, J.D., DE PATER, G., VAN OPSTAL, J., VOLDERS, P.G. & VOS, M.A. (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation, 110, 2453-2459.
39. THOMSEN, M.B., VOLDERS, P.G., STENGL, M., SPATJENS, R.L., BEEKMAN, J.D., BISCHOFF, U., KALL, M.A., FREDERIKSEN, K., MATZ, J. & VOS, M.A. (2003). Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J. Pharmacol. Exp. Ther., 307, 776-784.
40. USUI, T., SUGIYAMA, A., ISHIDA, Y., SATOH, Y., SASAKI, Y. & HASHIMOTO, K. (1998). Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels, 13, 49-57.
41. VAN DE WATER, A., VERHEYEN, J., XHONNEUX, R. & RENEMAN, R.S. (1989). An improved method to correct the QT interval of the electrocardiogram for change in heart rate. J. Pharmacol. Methods, 22, 207-217.
42. VERDUYN, S.C., RAMAKERS, C., SNOEP, G., LEUNISSEN, J.D., WELLENS, H.J. & VOS, M.A. (2001). Time course of structural adaptations in chronic AV block dogs: evidence for differential ventricular remodeling. Am. J. Physiol., 280, H2882-H2890.
43. + currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation, 100, 2455-2461.
44. VOS, M.A., DE GROOT, S.H., VERDUYN, S.C., VAN DER ZANDE, J., LEUNISSEN, H.D., CLEUTJENS, J.P., VAN BILSEN, M., DAEMEN, M.J., SCHREUDER, J.J., ALLESSIE, M.A. & WELLENS, H.J. (1998). Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation, 98, 1125-1135.
45. ZHANG, S., ZHOU, Z., GONG, Q., MAKIELSKI, J.C. & JANUARY, C.T. (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res., 84, 989-998.